Potential use of fucose-appended dendrimer/α-cyclodextrin conjugates as NF-κB decoy carriers for the treatment of lipopolysaccharide-induced fulminant hepatitis in mice
作者:Chiho Akao、Takahiro Tanaka、Risako Onodera、Ayumu Ohyama、Nana Sato、Keiichi Motoyama、Taishi Higashi、Hidetoshi Arima
DOI:10.1016/j.jconrel.2014.07.004
日期:2014.11
The purpose of the present study is to treat lipopolysaccharide (LPS)-induced fulminant hepatitis by NF-kappa B decoy complex with fucose-appended dendrimer (generation 2; G2) conjugate with alpha-cyclodextrin (Fuc-S-alpha-CDE (G2)). Fuc-S-alpha-CDE (G2, average degree of substitution of fucose (DSF2))/NF-kappa B decoy complex significantly suppressed nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production from LPS-stimulated NR8383 cells, a rat alveolar macrophage cell line, by adequate physicochemical properties and fucose receptor-mediated cellular uptake. Intravenous injection of Fuc-S-alpha-CDE (G2, DSF2)/NF-kappa B decoy complex extended the survival of LPS-induced fulminant hepatitis model mice. In addition, Fuc-S-alpha-CDE (G2, DSF2)/NF-kappa B decoy complex administered intravenously highly accumulated in the liver, compared to naked NF-kappa B decoy alone. Furthermore, the liver accumulation of Fuc-S-alpha-CDE (G2, DSF2)/NF-kappa B decoy complex was inhibited by the pretreatment with GdCl3, a specific inhibitor of Kupffer cell uptake. Also, the serum aspartate aminotransferase, alanine aminotransferase and TNF-alpha levels in LPS-induced fulminant hepatitis model mice were significantly attenuated by the treatment with Fuc-S-alpha-CDE (G2, DSF2)/NF-kappa B decoy complex, compared with naked NF-kappa B decoy alone. Taken together, these results suggest that Fuc-S-alpha-CDE (G2, DSF2) has the potential for a novel Kupffer cell-selective NF-kappa B decoy carrier for the treatment of LPS-induced fulminant hepatitis in mice. (C) 2014 Elsevier B.V. All rights reserved.